---
document_datetime: 2025-07-17 14:37:44
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ivabradine-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ivabradine-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8532443
conversion_datetime: 2025-12-23 07:07:52.897444
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ivabradine Zentiva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency ' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycle procedures,you mayneedto alsorefer toEPAR-Procedural steps taken andscientific information after authorisation (archive).

| Applicationnumber   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ² / amended on   | Product Information affected3   | Summary   |
|---------------------|-----------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc.Article61(3)-Accepted | 15/07/2025                          |                                            | PL                              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000284827   | Update of the package leaflet with revised contact details of local representatives. Furthermore,thePIhasbeenbroughtinline with the latest QRD template (version 10.4).   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|